1-4 of 4
Hang Quach, MD FRACP, FRCPA, MBBS
Close
Sort by
Journal Articles

CD4 + T Cell Fate in Multiple Myeloma

Rachel Elizabeth Cooke, BSc, FRACP, FRCPA, MBBS, Jessica Chung, PhD, Sarah Gabriel, PhD, Hang Quach, MD FRACP, FRCPA, MBBS, Simon J. Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, H. Miles Prince, MD FRACP, FRCPA, Rachel Koldej, PhD, David Ritchie, MBChB, PhD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 4494.
https://doi.org/10.1182/blood-2018-99-117674
Published: 2018
Journal Articles

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Hang Quach, MD FRACP, FRCPA, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP, FRCPA, MPhil, BA, Flora Yuen, BBiomedSc, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Edward S. Morris, BMBS, DM, Anna Kalff, MBBS, Krystal Bergin, Shreerang Sirdesai, MBBS, FRACP, FRCPA, Malgorzata Gorniak, BSc, Sridurga Mithraprabhu, PhD MSc, Tiffany Khong, BSc, PhD, John Reynolds, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3279.
https://doi.org/10.1182/blood-2018-99-113982
Published: 2018
Journal Articles

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Suzanne Lentzsch, MD PhD, Hang Quach, MD FRACP, FRCPA, MBBS, Marcelo Capra, MD PhD, Roberto Ovilla, MD, Jae-Cheol Jo, MD, Ho-Jin Shin, MD PhD, Pieter Sonneveld, MD PhD, Ming Qi, MD PhD, Himal Amin, Jianping Wang, Xiang Qin, Linda Okonkwo, Jon Ukropec, PhD, Sonali Trivedi, Kenshi Suzuki, MD PhD, Meletios A Dimopoulos, MD, Michele Cavo, MD, Ajay K Nooka, MD MPH, Ajai Chari, MD, Thierry Facon
Journal: Blood
Blood (2018) 132 (Supplement 1): 3288.
https://doi.org/10.1182/blood-2018-99-112669
Published: 2018
Journal Articles

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Timothy P. Hughes, MD, Eduardo Ciliao Munhoz, MD, Alaa Elhaddad, MD PhD, Ong Tee Chuan, MD, Kudrat Abdulkadyrov, MD, Jake Shortt, MD, Hang Quach, MD FRACP, FRCPA, MBBS, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Luis Meillon, MD, Lee-Yung Shih, MD Professor, Anna G. Turkina, MD PhD, Jonathan Hwang, PharmD, MBA, Prasanna Kumar Nidamarthy, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, PhD MD
Journal: Blood
Blood (2014) 124 (21): 4542.
https://doi.org/10.1182/blood.V124.21.4542.4542
Published: 2014